Revance Therapeutics Inc (RVNC)
3.16
-0.15
(-4.53%)
USD |
NASDAQ |
May 16, 16:00
3.16
0.00 (0.00%)
Pre-Market: 08:02
Revance Therapeutics Cash from Financing (TTM): 226.13M for March 31, 2024
Cash from Financing (TTM) Chart
Historical Cash from Financing (TTM) Data
Date | Value |
---|---|
March 31, 2024 | 226.13M |
December 31, 2023 | 136.57M |
September 30, 2023 | 132.02M |
June 30, 2023 | 305.95M |
March 31, 2023 | 229.65M |
December 31, 2022 | 331.69M |
September 30, 2022 | 338.27M |
June 30, 2022 | 124.39M |
March 31, 2022 | 106.14M |
December 31, 2021 | 29.87M |
September 30, 2021 | 96.79M |
June 30, 2021 | 98.59M |
March 31, 2021 | 96.18M |
December 31, 2020 | 331.48M |
September 30, 2020 | 378.99M |
June 30, 2020 | 379.59M |
March 31, 2020 | 379.14M |
December 31, 2019 | 221.66M |
September 30, 2019 | 106.99M |
June 30, 2019 | 107.97M |
March 31, 2019 | 110.87M |
Date | Value |
---|---|
December 31, 2018 | 1.782M |
September 30, 2018 | 160.28M |
June 30, 2018 | 168.51M |
March 31, 2018 | 168.72M |
December 31, 2017 | 195.94M |
September 30, 2017 | 36.61M |
June 30, 2017 | 26.82M |
March 31, 2017 | 22.96M |
December 31, 2016 | -2.642M |
September 30, 2016 | 125.08M |
June 30, 2016 | 135.09M |
March 31, 2016 | 144.55M |
December 31, 2015 | 142.59M |
September 30, 2015 | 9.74M |
June 30, 2015 | -0.716M |
March 31, 2015 | 120.57M |
December 31, 2014 | 229.09M |
September 30, 2014 | 254.68M |
June 30, 2014 | 253.60M |
March 31, 2014 | 130.29M |
December 31, 2013 | 53.99M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (TTM) Range, Past 5 Years
29.87M
Minimum
Dec 2021
379.59M
Maximum
Jun 2020
207.90M
Average
179.11M
Median
Cash from Financing (TTM) Benchmarks
AbbVie Inc | -211.00M |
Eli Lilly and Co | 2.772B |
Aquestive Therapeutics Inc | 94.92M |
Humacyte Inc | 67.71M |
AN2 Therapeutics Inc | 85.14M |